EZH2 and central nervous system cancer: Similarly, Pyo et al. (2017), in their meta-analysis involving 12 eligible studies, concluded that EZH2 positivity (by immunohistochemistry or polymerase chain reaction) was significantly correlated with WHO tumour grade and conferred a worse prognosis in patients with gliomas [21].